scispace - formally typeset
C

Carlos Castaño

Researcher at Autonomous University of Barcelona

Publications -  59
Citations -  7078

Carlos Castaño is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Stroke & Modified Rankin Scale. The author has an hindex of 15, co-authored 49 publications receiving 5610 citations. Previous affiliations of Carlos Castaño include Bellvitge University Hospital & Polytechnic University of Catalonia.

Papers
More filters
Journal ArticleDOI

Thrombectomy within 8 hours after symptom onset in ischemic stroke

TL;DR: Among patients with anterior circulation stroke who could be treated within 8 hours after symptom onset, stent retriever thrombectomy reduced the severity of post-stroke disability and increased the rate of functional independence.
Journal ArticleDOI

Mechanical Thrombectomy With the Solitaire AB Device in Large Artery Occlusions of the Anterior Circulation A Pilot Study

TL;DR: The results suggest that the Solitaire AB device can rapidly, safely, and effectively retrieve clots from the middle cerebral artery and terminus internal carotid artery within 8 hours from symptoms onset.
Journal ArticleDOI

Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data

Bruce C.V. Campbell, +1296 more
- 01 Jan 2019 - 
TL;DR: Estimated ischaemic core volume was independently associated with functional independence and functional improvement but did not modify the treatment benefit of endovascular thrombectomy over standard medical therapy for improved functional outcome.
Journal ArticleDOI

Prospective, Multicenter, Single-Arm Study of Mechanical Thrombectomy Using Solitaire Flow Restoration in Acute Ischemic Stroke

TL;DR: In this single-arm study, treatment with the Solitaire Flow Restoration device in intracranial anterior circulation occlusions results in high rates of revascularization, low risk of clinically relevant procedural complications, and good clinical outcomes in combination with low mortality at 90 days.